Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its patented therapy LUCID-MS for the treatment of multiple sclerosis (MS), a chronic autoimmune and neurodegenerative disease that affects more than 2.8 million people worldwide and approximately 1 million in the USA. The company recently announced the completion of phase 1 clinical studies involving healthy volunteers, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated.
Multiple sclerosis remains one of the most challenging neurological diseases because of its progressive nature, unpredictable course and lack of a cure. Current treatments often focus on reducing inflammation and relapse frequency but may not adequately address the underlying neurodegeneration and myelin damage that drive long-term disease progression. Quantum BioPharma’s LUCID-MS program is built around the unmet need for MS therapies capable of directly protecting or restoring myelin integrity that affects the loss of mobility or control of a person’s body.
The company reached a significant milestone in April 2026 when it announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS. This submission marks a crucial step toward initiating clinical trials in MS patients and potentially bringing a novel therapeutic option to the market.
LUCID-MS is designed to target demyelination and provide neuroprotection in multiple sclerosis, addressing the loss of mobility and function of one’s body. By focusing on myelin repair, the therapy aims to halt or reverse the damage that leads to disability progression, offering hope to patients who continue to experience worsening symptoms despite available immune-modulating therapies.
For more information on Quantum BioPharma and its latest developments, visit the company’s newsroom at https://ibn.fm/QNTM.
